What is HC Wainwright’s Forecast for HeartBeam Q2 Earnings?

HeartBeam, Inc. (NASDAQ:BEAT) – HC Wainwright boosted their Q2 2026 earnings per share estimates for shares of HeartBeam in a report released on Friday, May 22nd. HC Wainwright analyst Y. Chen now anticipates that the medical research company will earn ($0.11) per share for the quarter, up from their previous estimate of ($0.12). HC Wainwright currently has a “Buy” rating and a $2.50 target price on the stock. The consensus estimate for HeartBeam’s current full-year earnings is ($0.39) per share. HC Wainwright also issued estimates for HeartBeam’s Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.41) EPS, Q1 2027 earnings at ($0.09) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.07) EPS and FY2027 earnings at ($0.31) EPS.

HeartBeam (NASDAQ:BEAT) last issued its quarterly earnings results on Wednesday, May 13th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02.

Several other equities research analysts have also issued reports on the company. Wall Street Zen raised HeartBeam from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Benchmark lowered their target price on shares of HeartBeam from $8.00 to $5.00 and set a “speculative buy” rating for the company in a research note on Friday, May 15th. B. Riley Financial started coverage on shares of HeartBeam in a research report on Tuesday, March 31st. They issued a “buy” rating and a $4.00 price target on the stock. Finally, D. Boral Capital downgraded HeartBeam from a “buy” rating to a “hold” rating in a research note on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, HeartBeam has an average rating of “Moderate Buy” and a consensus price target of $4.33.

HeartBeam Stock Performance

NASDAQ:BEAT opened at $0.89 on Wednesday. The company has a market capitalization of $49.58 million, a price-to-earnings ratio of -1.59 and a beta of -0.86. HeartBeam has a one year low of $0.54 and a one year high of $4.00. The stock has a 50-day simple moving average of $1.03 and a 200 day simple moving average of $1.47.

Insider Activity

In other HeartBeam news, Director Richard Ferrari bought 62,500 shares of the stock in a transaction that occurred on Thursday, April 16th. The shares were purchased at an average cost of $0.80 per share, for a total transaction of $50,000.00. Following the transaction, the director directly owned 291,636 shares in the company, valued at $233,308.80. The trade was a 27.28% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Willem Elfrink bought 187,500 shares of the business’s stock in a transaction on Thursday, April 16th. The shares were acquired at an average cost of $0.80 per share, for a total transaction of $150,000.00. Following the purchase, the director directly owned 538,667 shares in the company, valued at $430,933.60. This represents a 53.39% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have acquired 1,118,750 shares of company stock valued at $895,000. Insiders own 18.04% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of BEAT. Sigma Planning Corp lifted its holdings in HeartBeam by 115.0% in the first quarter. Sigma Planning Corp now owns 132,550 shares of the medical research company’s stock worth $162,000 after purchasing an additional 70,900 shares during the period. Ritholtz Wealth Management raised its position in shares of HeartBeam by 49.6% during the 4th quarter. Ritholtz Wealth Management now owns 208,191 shares of the medical research company’s stock worth $500,000 after buying an additional 69,009 shares in the last quarter. Raymond James Financial Inc. raised its position in shares of HeartBeam by 212.5% during the 3rd quarter. Raymond James Financial Inc. now owns 88,050 shares of the medical research company’s stock worth $145,000 after buying an additional 59,872 shares in the last quarter. State Street Corp lifted its stake in shares of HeartBeam by 60.1% in the 4th quarter. State Street Corp now owns 125,473 shares of the medical research company’s stock worth $301,000 after acquiring an additional 47,100 shares during the period. Finally, Kestra Private Wealth Services LLC boosted its holdings in shares of HeartBeam by 23.4% in the third quarter. Kestra Private Wealth Services LLC now owns 175,989 shares of the medical research company’s stock valued at $290,000 after acquiring an additional 33,344 shares in the last quarter. 7.77% of the stock is owned by institutional investors and hedge funds.

About HeartBeam

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors.